Get the Stockscreener App
3.9397
1.26%
0.0497
X 4 Pharmaceuticals Inc stock is traded at $3.9397, with a volume of 213.90K.
It is up +1.26% in the last 24 hours and up +11.59% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.89
Open:
$3.89
24h Volume:
213.90K
Relative Volume:
0.25
Market Cap:
$344.50M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.41
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
+4.07%
1M Performance:
+11.59%
6M Performance:
+22.91%
1Y Performance:
-82.74%
1-Day Range:
$3.84
$3.98
1-Week Range:
$3.525
$4.07
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.94 | 340.13M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.29 | 112.81B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
738.38 | 76.32B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
891.84 | 54.80B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.06 | 53.43B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
193.96 | 40.49B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews
Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - Setenews
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat
Blood pressure drug recalled for possible cross-contamination - USA Today
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
XFOR Stock Update: Stifel Raises Target Price to $10.00 | XFOR S - GuruFocus
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - BioSpace
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
How X4 Pharmaceuticals Inc. stock reacts to oil prices2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Is X4 Pharmaceuticals Inc. (48Q0) stock a safe buy pre earningsFed Meeting & Intraday High Probability Alerts - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - Setenews
Why pension funds invest in X4 Pharmaceuticals Inc. (48Q0) stockWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - Newser
Is X4 Pharmaceuticals Inc. stock positioned for long term growthJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Will X4 Pharmaceuticals Inc. (48Q0) stock profit from AI boomTrade Ideas & Fast Exit and Entry Strategy Plans - Newser
An analyst sees good growth prospects for Nano X Imaging Ltd (NNOX) - Setenews
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Wall Street Zen - Defense World
Layoff Tracker: Valneva Terminates 30 Amid Site Closure - BioSpace
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Momentum Check & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - Morningstar
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROE2025 Macro Impact & Low Volatility Stock Recommendations - moha.gov.vn
Earnings Report: Can X4 Pharmaceuticals Inc. stock sustain institutional interestTrade Risk Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31% - simplywall.st
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance
Head-To-Head Contrast: Werewolf Therapeutics (NASDAQ:HOWL) versus X4 Pharmaceuticals (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen - Defense World
Is X4 Pharmaceuticals Inc. stock positioned for digital transformation2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedWeekly Trend Report & AI Enhanced Trading Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews
How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
WHIM Syndrome Research Analysis Report 2025-2035: Market Advances as X4 Pharmaceuticals Leads Innovation in CXCR4-Targeted Therapies - Yahoo Finance
Prescription Drug Costs - Britannica
What moving averages say about X4 Pharmaceuticals Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.27%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):